5

15

## Claims

- 1. A method for treating an individual suffering from or having a tendency to develop a food allergy comprising administering to said individual a therapeutically effective amount of a modified food allergen, wherein the food allergen is modified by reduction and alkylation.
- 2. A method according to claim 1, wherein the food allergen is an allergenic food protein.
- 3. A method according to claim 1 or 2, wherein the food allergen is a seed storage protein.
- 4. A method according to claim 3, wherein the storage protein is a 2S albumin, lipid transfer protein (LTP), or conglutin.
  - 5. A method according to claim 4, wherein the storage protein is a tree nut or seed 2S albumin.
  - 6. A method according to claim 5, wherein the storage protein is brazil nut 2S albumin.
    - 7. A method according to any of the preceding claims, wherein the food allergen is modified by reduction using a reducing agent chosen from the group of 2-mercaptoethanol, dithiothreitol, dithioerythritol, tributylphosphine, and a combination thereof.
- 20 8. A method according to any of the preceding claims, wherein the food allergen is modified by alkylation using an alkylating agent chosen from the group of N-ethylmalimide, cystamine, iodoacetamide, iodoacetic acid and combinations thereof.
- 9. A method according to any of the preceding claims, wherein the modified food allergen is administered in the form of a dosage form chosen from the group of a capsule, tablet, lozenge, dragee, pill, droplets, suppository, aerosol, powder, spray, vaccine, ointment, paste, cream, inhalant, or patch.

WO 2005/060994 PCT/NL2004/000892

24

- 10. A method according to claim 9, wherein the dosage form further comprises a pharmaceutically acceptable carrier and/or an adjuvant.
- 11. A method according to any of the preceding claims, wherein the modified food allergen is administered orally, intraperitoneally,
- 5 subcutaneously, intravenously, intramuscularly, pulmonarily, or via mucosa.
  - 12. A method according to any of the preceding claims, wherein the modified food allergen induces production of Thelper-1 mediated subclasses of IgG antibodies.
- 13. A method according to any of the preceding claims, wherein the production of IgE antibodies is down-regulated.

15

- 14. A food allergen modified by reduction and alkylation for use in a method according to any of the preceding claims.
- 15. A pharmaceutical composition comprising an food allergen modified by reduction and alkylation for use in a method according to any of the claims 1-13.
- Use of a food allergen modified by reduction and alkylation for the manufacture of a medicament for immunotherapy treatment of a food allergy brought about by the native form of said allergenic protein.